Related Experiment Video
Updated: May 6, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Translational Molecular Imaging of Prostate Cancer
Ana P Kiess1, Steve Y Cho, Martin G Pomper
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract:
Prostate cancer is a heterogeneous disease, and its management is now evolving to become more personalized and to incorporate new targeted therapies. With these new changes comes a demand for molecular imaging techniques that can not only detect disease but also assess biology and treatment response. This review article summarizes current molecular imaging approaches in prostate cancer (e.g. 99mTc bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography) and highlights emerging clinical and preclinical imaging agents, with an emphasis on mechanism and clinical application. Emerging agents at various stages of clinical translation include radiolabeled analogs of lipid, amino acid, and nucleoside metabolism, as well as agents more specifically targeting prostate cancer biomarkers including androgen receptor, prostate-specific membrane antigen and others. We also highlight new techniques and targeted contrast agents for magnetic resonance imaging and spectroscopy. For all these imaging techniques, a growing and important unmet need is for well-designed prospective clinical trials to establish clear indications with clinical benefit in prostate cancer.
Insights
Molecular imaging advances prostate cancer care by assessing disease biology and treatment response. Emerging agents and techniques show promise, but clinical trials are needed to confirm benefits.
Area of Science:
- Oncology
- Radiology
- Molecular Imaging
Background:
- Prostate cancer management is shifting towards personalized medicine and targeted therapies.
- This evolution necessitates advanced molecular imaging for disease detection, biological assessment, and treatment response monitoring.
Purpose of the Study:
- To review current molecular imaging techniques for prostate cancer.
- To highlight emerging imaging agents and their mechanisms and clinical applications.
- To discuss new magnetic resonance imaging and spectroscopy techniques.
Main Methods:
- Review of existing literature on molecular imaging in prostate cancer.
- Summary of established techniques like bone scintigraphy and FDG-PET.
- Discussion of emerging agents targeting metabolism and specific biomarkers (androgen receptor, PSMA).
Main Results:
- Current imaging includes bone scintigraphy and FDG-PET.
- Emerging agents target lipid, amino acid, and nucleoside metabolism.
- Novel agents target prostate cancer biomarkers like androgen receptor and PSMA.
- Advanced MRI and spectroscopy techniques are also being developed.
Conclusions:
- Molecular imaging is crucial for personalized prostate cancer management.
- Emerging agents and techniques offer potential for improved detection and assessment.
- Well-designed prospective clinical trials are essential to establish clear indications and clinical utility.
